Clinical trials
Basal Cell Carcinoma of Skin clinical trials
Below are recruiting basal cell carcinoma of skin clinical trials, each written for real people, not researchers. We’re tracking 273 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT04780568RecruitingPhase 1
First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Columbus, OhioAges 18 years+ - NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Queen Creek, ArizonaAges 18 years+ - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT07807956RecruitingPhase 1
Intravenous study drug for advanced solid tumors
This trial tests an investigational drug given through an IV to see if it can help people with advanced solid tumors. It aims to learn about side effects, how the drug works in the body, and whether it can slow or shrink the cancer.
Grand Rapids, MichiganAges 18 years+ - NCT05044117RecruitingPhase 3
Capecitabine pills after chemoradiation for head and neck cancer
This trial tests whether taking capecitabine pills on a steady, low schedule after standard treatment can help keep locally advanced head and neck squamous cell cancer from coming back or spreading. You may be eligible if your cancer is stage III–IV and you have finished certain radiation/chemo treatments on time, without current spread.
Guangzhou, GuangdongAges 18–70 - NCT05507411RecruitingPhase 2
Watch-and-wait after chemo-radiation plus immunotherapy for esophagus cancer
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
Hanzhou, ZhejiangAges 18–75 - NCT04992559RecruitingPhase 2
Toripalimab after surgery and chemoradiation for head and neck cancer
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
Guangzhou, GuangdongAges 18–70 - NCT05817903RecruitingPhase 2
Nivolumab with or without axitinib after prior nivolumab
This Phase 2 trial studies whether adding axitinib to nivolumab (or giving nivolumab alone) can better control advanced clear-cell kidney cancer after standard initial treatment with nivolumab plus ipilimumab. It may help by extending response or slowing tumor growth while improving how long treatment works.
BresciaAges 18 years+ - NCT05854823Recruiting
Reduced radiation after surgery for advanced head and neck cancer
This trial looks at whether giving less (de-escalated) radiation after surgery is as effective and safer for people with locally advanced head and neck squamous cell carcinoma who had a strong response to treatment before surgery. If you had no remaining cancer or only very small amounts of cancer left in the surgical specimen, this approach may help reduce side effects while keeping control of the disease.
Zhuhai, GuangdongAges 18–70 - NCT05941338RecruitingPhase 2
Tirelizumab plus chemotherapy before head and neck surgery
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
Guangzhou, GuangdongAges 18–65 - NCT05837052RecruitingPhase 2
Serplulimab plus chemo after initial treatment for lung cancer
This Phase 2 study looks at how safe and effective serplulimab (an immune medicine) combined with chemotherapy is when used as a “conversion” plan—first shrinking lung cancer, then trying to remove the main tumor with surgery. It may help some people who are not initially good candidates for surgery or focused radiation to become eligible after treatment.
Hangzhou, ZhejiangAges 18–75 - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06190639RecruitingPhase 2
Sintilimab after surgery for node-positive esophageal cancer
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hangzhou, ZhejiangAges 18 years+ - NCT06240689RecruitingPhase 2
Immune maintenance therapy after chemoradiotherapy for head and neck cancer
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
Hangzhou, ZhejiangAges 18–75 - NCT05515315RecruitingPhase 2
Immunotherapy plus chemo then chemoradiation for esophageal cancer
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Fuzhou, FujianAges 18–70 - NCT06410651RecruitingPhase 2
Nimotuzumab with chemoradiation for advanced esophageal cancer
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
BeijingAges 18–80 - NCT06353685RecruitingPhase 2
Less radiation after surgery for oral cancer with good response
This trial is testing whether giving less radiation after surgery is safe and effective for people with oral cancer whose surgery results were very good (no cancer cells or very few left). It aims to reduce side effects while still preventing cancer from coming back.
GuangzhouAges 18–80 - NCT06110572RecruitingPhase 1/Phase 2
Total body irradiation with immunotherapy for extensive SCLC
This trial adds total body irradiation (a low dose of radiation to the whole body) to standard atezolizumab (immunotherapy) plus chemotherapy for people with extensive-stage small cell lung cancer. The goal is to see if the radiation helps the immunotherapy work better.
Nashville, TennesseeAges 18 years+ - NCT04688528Recruiting
Radiation planning to spare the opposite neck in head cancer
This trial tests a safer radiation plan that may reduce dose to the opposite (other) side of the neck while still treating the cancer spread risk. It uses special mapping to guide treatment and looks at patients whose cancer is already in an involved lymph node on one side.
Genk, LimburgAges 18 years+ - NCT06385730RecruitingPhase 2
PD-1 blocker before surgery for elderly esophageal cancer
This trial tests a drug (PD-1 blocker) given before surgery for people over 75 with esophageal cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 76 years+ - NCT07811752RecruitingPhase 2
Combination treatment for advanced esophageal cancer
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
ShanghaiAges 18 years+ - NCT06354140RecruitingPhase 2
Tislelizumab plus S-1 for esophageal cancer after surgery
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07796113RecruitingPhase 2
Study of adebrelimab plus famitinib and chemo before surgery for esophageal cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (famitinib) with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
Xi'an, ShannxiAges 18–75
Hear when a new Basal Cell Carcinoma of Skin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for basal cell carcinoma of skin?
- Yes. Clin2 currently lists 273 recruiting basal cell carcinoma of skin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a basal cell carcinoma of skin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a basal cell carcinoma of skin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.